Loading…
Olema Pharmaceuticals, Inc. is projected to rise to $13.06 by 2027, a +1% move from its current price of $12.91. OLMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.56 | $12.92 | $13.29 | +0.07% |
| May 30 | $12.42 | $12.93 | $13.46 | +0.14% |
| May 31 | $12.31 | $12.94 | $13.59 | +0.21% |
| Jun 1 | $12.23 | $12.95 | $13.71 | +0.28% |
| Jun 2 | $12.16 | $12.96 | $13.81 | +0.35% |
| Jun 3 | $12.09 | $12.96 | $13.90 | +0.42% |
| Jun 4 | $12.03 | $12.97 | $13.99 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.03 | $12.97 | $13.99 | +0.49% |
| Week 2 | $11.72 | $13.04 | $14.51 | +0.99% |
| Week 3 | $11.50 | $13.10 | $14.93 | +1.49% |
| Week 4 | $11.32 | $13.17 | $15.31 | +1.99% |
| Week 5 | $11.18 | $13.23 | $15.66 | +2.49% |
| Week 6 | $11.05 | $13.30 | $16.00 | +3.00% |
| Week 7 | $10.94 | $13.36 | $16.32 | +3.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, in Phase 3 clinical trials for ER-positive, HER2-negative breast cancer.
OPERA-01 is the pivotal Phase 3 trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer, and palazestrant is also being studied with CDK4/6 inhibitors, a PI3K alpha inhibitor, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor in Phase 1b/2 trials.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. (OLMA) is a Healthcare stock with a current price of $13.68 and a market cap of $1.19B. It is ranked 2394.
The latest fundamentals place OLMA in the small-cap to mid-cap zone, with a price setup that the forecast envisions evolving over the coming years. The year-by-year forecast shows gradual upside through 2030 and notable upside by 2040 and 2050, with maximum price projections and ROI figures provided for several milestones.
A major floor 20.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 30.3% above — a clean break opens room to run.
A major ceiling 110.2% above — clearing it would confirm fresh momentum.
Key OLMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OLMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.63 | Sell | $13.42 | Sell |
| MA 10 | $13.52 | Sell | $13.65 | Sell |
| MA 20 | $14.07 | Sell | $14.08 | Sell |
| MA 50 | $14.79 | Sell | $15.56 | Sell |
| MA 100 | $19.41 | Sell | $16.92 | Sell |
| MA 200 | $16.65 | Sell | $16.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.95 | Neutral |
| Stoch RSI (14) | 34.01 | Neutral |
| CCI (20) | -137.32 | Sell |
| Williams %R (14) | -99.55 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -13.36 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.45 | Buy |
| TRIX (15) | -0.54 | Sell |
| Awesome (5,34) | -1.26 | Sell |
| Ultimate (7,14,28) | 34.51 | Neutral |
| Momentum (10) | -1.06 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 13.57 | Sell |
| ADX (14) | 22.36 | Sell |
| ATR (14) | 0.38 | Info |
Sentiment in the near term is NEUTRAL. The RSI14 is 40, with a 50-day simple moving average (SMA) of $14.89 and a 200-day SMA of $16.56.
In the near term, the stock trades within a 30-day range of $11.34 to $16.50, with support at $12.90 and resistance at $16.82.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.90 | $12.91 | $16.40 | 0% | Neutral | |
| $10.31 | $13.06 | $17.55 | +1% | Neutral | |
| $10.02 | $13.06 | $18.20 | +1% | Neutral | |
| $9.87 | $13.17 | $18.90 | +2% | Neutral | |
| $9.97 | $13.59 | $20.00 | +5% | Neutral | |
| $11.80 | $16.39 | $24.65 | +27% | Bullish | |
| $12.79 | $18.10 | $27.75 | +40% | Bullish | |
| $12.26 | $17.65 | $27.54 | +37% | Bullish | |
| $12.42 | $18.16 | $28.81 | +41% | Bullish | |
| $11.93 | $17.73 | $28.54 | +37% | Bullish | |
| $16.95 | $27.04 | $46.37 | +109% | Bullish | |
| $22.40 | $40.39 | $75.96 | +213% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.90 | $12.91 | $15.17 | +0.00% |
| June 2026 | $11.32 | $13.31 | $16.03 | +3.09% |
| July 2026 | $11.61 | $13.77 | $16.81 | +3.43% |
| August 2026 | $11.36 | $13.57 | $16.75 | -1.44% |
| September 2026 | $11.11 | $13.34 | $16.62 | -1.66% |
| October 2026 | $11.21 | $13.53 | $16.98 | +1.39% |
| November 2026 | $11.06 | $13.41 | $16.95 | -0.89% |
| December 2026 | $10.58 | $12.89 | $16.40 | -3.85% |
Click any year to see its month-by-month OLMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect OLMA to range from $12.90 to $16.40 through 2026. The $12.91 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The OLMA price prediction for 2027 points to an average of $13.06 (low $10.31, high $17.55) — a potential gain of +1% on today's $12.91. A consolidation phase looks the most probable path here.
In 2028, OLMA is projected to trade between $10.02 and $18.20, averaging $13.06 — a potential gain of +1% from today's $12.91. That is 0% versus the projected 2027 average. Price action looks broadly range-bound.
Olema Pharmaceuticals, Inc.'s 2029 outlook centres on $13.17, within a $9.87 to $18.90 range. That is up +1% on the projected 2028 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, OLMA could reach as high as $20.00, with a base case around $13.59 and support toward $9.97 — roughly +5% from $12.91. Price action looks broadly range-bound.
Expect OLMA to range from $11.80 to $24.65 through 2031. The $16.39 average target implies a +27% move from current prices. That is up +21% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The OLMA price prediction for 2032 points to an average of $18.10 (low $12.79, high $27.75) — a potential gain of +40% on today's $12.91. Momentum favours further upside here.
In 2033, OLMA is projected to trade between $12.26 and $27.54, averaging $17.65 — a potential gain of +37% from today's $12.91. That is -2% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Olema Pharmaceuticals, Inc.'s 2034 outlook centres on $18.16, within a $12.42 to $28.81 range. That is up +3% on the projected 2033 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2035, OLMA could reach as high as $28.54, with a base case around $17.73 and support toward $11.93 — roughly +37% from $12.91. Buyers look set to stay in control over this stretch.
Expect OLMA to range from $16.95 to $46.37 through 2040. The $27.04 average target implies a +109% move from current prices. That is up +53% on the projected 2035 average. Momentum favours further upside here.
The OLMA price prediction for 2050 points to an average of $40.39 (low $22.40, high $75.96) — a potential gain of +213% on today's $12.91. Buyers look set to stay in control over this stretch.
Investing $1,000 in OLMA today (≈ 77.459334 OLMA) could be worth
$3,128.44
+$2,128.44 (+213%) by 2050 · US Dollar
Based on the average projected OLMA price of $40.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OLMAwould be worth at today's price.
$1,000 invested in OLMA on May 27, 2025 (≈ 194.174754 OLMA) would be worth
$2,506.8
+$1,506.8 (+150.7%) today · 2.51× · US Dollar
Based on a OLMA entry price of $5.15 vs. today's $12.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.96 | $924.79 | -7.5% |
| 1 month ago | $15.29 | $844.34 | -15.6% |
| 3 months ago | $24.39 | $529.32 | -47.1% |
| 6 months ago | $28.32 | $455.86 | -54.4% |
| 1 year ago | $5.15 | $2,506.8 | +150.7% |
| All time (5.0y) ago | $27.64 | $467.08 | -53.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OLMA forecast.
Our base-case forecast reaches $26.00 around 2040.
Implied market cap at $26.00: $2.27B
The multi-year forecast shows a progression from neutral to bullish sentiment starting in 2031, with higher average prices and meaningful ROIs in the later years. For 2030 the avg is $15.13 with a 10.6% ROI, and the 2031–2035 period improves into the high-teens and low-twenties as bullish momentum develops. The 2031 avg is $18.13 with a 32.5% ROI, the 2032 avg is $19.95 with a 45.8% ROI, the 2033 avg is $19.58 with a 43.1% ROI, the 2034 avg is $20.03 with a 46.4% ROI, and the 2035 avg is $19.74 with a 44.3% ROI.
The forecast shows substantial upside by 2040, with an avg of $30.32 and a 121.6% ROI, and by 2050, with an avg of $46.40 and a 239.2% ROI. The 2040 max is $51.97 and the 2050 max is $87.20, underscoring potential long-run upside while recognizing these are estimates, not guarantees. The sentiment remains bullish for 2040 and 2050, reflecting the projected acceleration in value over the long term.
Tap a question to reveal the answer.
The 2030 forecast shows min $11.10, avg $15.13, max $22.26 with an ROI of 10.6% and a NEUTRAL sentiment.
The forecast indicates mixed near-term returns with neutral outlook through 2030, followed by bullish sentiment from 2031 onward. For example, 2031 avg $18.13 with a 32.5% ROI, 2040 avg $30.32 with a 121.6% ROI, and 2050 avg $46.40 with a 239.2% ROI.
Yes. The 2040 max forecast is $51.97, which is above $50.
Current price is $13.68 and market cap is $1.19B.
2031 is Bullish, 2032 is Bullish, 2033 is Bullish, 2034 is Bullish, and 2035 is Bullish.
Olema Pharmaceuticals, Inc. Community Discussion
0Share your Olema Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.